Nextcure Stock Price, News & Analysis

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company focused on innovative immunotherapies, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on December 7, 2021, at 11:40 am ET. Investors can access the live audio webcast through the company’s website, with a replay available for 30 days post-event. NextCure aims to develop first-in-class immunomedicines targeting cancer and immune-related diseases, using its proprietary FIND-IO™ platform to explore various immune cell types.

NextCure, a clinical-stage biopharmaceutical company focused on immunomedicines for cancer and immune-related diseases, will participate in the Piper Sandler Virtual 32nd Annual Healthcare Conference on November 30. An audio webcast of the fireside chat will be available on the company’s website starting at 10 a.m. ET and archived for 30 days. NextCure utilizes its proprietary FIND-IO™ platform to discover novel immunomedicines targeting patients who do not respond to existing cancer therapies.

NextCure, Inc. (Nasdaq: NXTC) presented promising new data on its immunomedicines NC318 and NC410 at the Society for Immunotherapy of Cancer meeting. NC318, targeting Siglec-15, showed a 37% disease control rate and a median progression-free survival of 5.0 months in advanced solid tumors. Interim results for NC410 highlighted its safety and immune modulation potential with no dose-limiting toxicities. Collaborative non-clinical research indicated anti-tumor activity through immune system activation. NextCure aims to improve treatment options for cancer patients.

NextCure, Inc. (Nasdaq: NXTC) reported its Q3 2021 financial results, showing a net loss of $17.9 million, up from $16.4 million in Q3 2020. Cash reserves decreased to $235.3 million from $283.4 million at the end of 2020, mainly due to operational costs. R&D expenses rose to $13.6 million, reflecting higher clinical trial costs. The company will present data for its NC318 and NC410 programs at the SITC annual meeting and host an R&D update on November 15, 2021. They expect their cash to sustain operations into the second half of 2023.

NextCure, Inc. (NXTC) announced it will present new data from two studies at the 63rd American Society of Hematology annual meeting from December 11-14, 2021. The studies focus on the role of Siglec-15 in childhood leukemia and the effects of LAIR-1 monoclonal antibodies in acute myeloid leukemia, in collaboration with Emory and Vanderbilt Universities. These findings aim to advance the understanding and treatment of these cancers, specifically for patients not adequately addressed by existing therapies.

NextCure, a clinical-stage biopharmaceutical company (Nasdaq: NXTC), will hold a Virtual Oncology Pipeline Update Event on November 15, 2021, at 4:30 p.m. ET. The event aims to provide insights into its oncology pipeline, including data from the Society for Immunotherapy of Cancer’s 36th Annual Meeting. Dr. Roy Herbst will address unmet needs in lung cancer treatment. Participants can join via conference call or webcast, with a replay available for 30 days after the event.

NextCure, Inc. (Nasdaq: NXTC) appointed Elizabeth Jaffee, M.D., Ursula Matulonis, M.D., and Weiping Zou, M.D., Ph.D., to its Scientific Advisory Board (SAB) while Ethan Shevach, M.D., retires. These new members bring extensive experience in oncology and immunology, crucial for advancing NextCure's clinical programs. Dr. Jaffee focuses on immune-based therapies, Dr. Matulonis on targeted therapies for gynecologic cancers, and Dr. Zou on cancer immunology. NextCure aims to enhance its capabilities in developing first-in-class immunomedicines.

NextCure, a clinical-stage biopharmaceutical company, announced the publication of preclinical data in Frontiers in Immunology regarding NC410, a first-in-class immunomedicine. The study indicates that collagen fragments in cancer can suppress T cell activity via LAIR-1, but this effect can be reversed by LAIR-2 and NC410. Currently in a Phase 1/2 clinical trial for advanced solid tumors, NC410 aims to provide a new therapeutic option for patients resistant to existing immunotherapies. Initial clinical data will be shared at a conference in November.

NextCure, Inc. (Nasdaq: NXTC) announced the appointment of Dr. Ellen G. Feigal and Dr. Anne Borgman to its Board of Directors, bringing extensive experience in clinical and biopharmaceutical sectors. This change follows the resignation of Dr. Stella Xu. Dr. Feigal specializes in biologics and oncology, while Dr. Borgman has leadership experience in hematology and oncology drug development. Both appointments aim to support NextCure's ongoing clinical programs and the advancement of new immunomedicines for cancer treatment.